Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This is a national, randomized, web-based, double-blind study to determine whether erlotinib
(Tarceva) compared to placebo improves progression-free survival (PFS) for patients with
inoperable, stage III NSCLC following concurrent docetaxel, carboplatin and thoracic
radiotherapy. We hypothesize that the introduction of this orally active, well-tolerated
agent following concurrent chemoradiation and prior to the emergence of drug resistance will
prolong the progression-free survival by 40% (10 months → 14 months).